
vTv Therapeutics (VTVT) Stock Forecast & Price Target
vTv Therapeutics (VTVT) Analyst Ratings
Bulls say
vTv Therapeutics Inc is advancing its clinical pipeline with the lead candidate, cadisegliatin (TTP399), positioned as a unique late-stage therapy for type 1 diabetes, which could enhance its market appeal. Positive momentum in the company’s valuation is underscored by a raised risk-adjusted DCF valuation reflecting an increase in estimated peak market penetration from 20% to 25%. The company's ongoing studies, including the successful progression of the CATT1 trial, along with insights gained from Phase 2 trials of similar therapeutics, bolster confidence in the safety and efficacy of its pipeline, suggesting a promising outlook for both cadisegliatin and other candidates.
Bears say
vTv Therapeutics Inc's stock presents a negative outlook primarily due to the substantial clinical risks associated with its lead candidate, cadisegliatin (TTP399), which remains in late-stage development but faces challenges such as potential safety findings and efficacy concerns that have not been observed in earlier studies. The historical performance of first-generation glucokinase activators, which faced significant issues including excess hypoglycemia and diminishing glycemic benefits over time, raises further doubts about the long-term viability of vTv's approach in a competitive market. Additionally, the overall failure of a large percentage of adults with type 1 diabetes to achieve recommended glycemic control suggests a difficult therapeutic landscape, diminishing the prospects for successful market adoption of vTv's drug candidates.
This aggregate rating is based on analysts' research of vTv Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
vTv Therapeutics (VTVT) Analyst Forecast & Price Prediction
Start investing in vTv Therapeutics (VTVT)
Order type
Buy in
Order amount
Est. shares
0 shares